Genmab 9M Revenue Up 22% to $3,238M; Net Profit Falls to $698M on Merus Costs
GMAB has more than doubled off its 52-week low of $23.62 on light trading volume (0.4× avg).
Summary
Genmab's nine-month revenue rose 22% to $3,238 million on DARZALEX and EPKINLY strength, but net profit fell to $698 million as Merus integration costs and $324 million of acquisition-debt interest weighed. Full-year guidance was maintained.
Key Events · Earnings and Guidance · GMAB
-
Nine-Month Revenue Up 22%
Revenue reached $3,238 million for the first nine months of 2026 versus $2,662 million a year earlier, a $576 million increase driven by DARZALEX and Kesimpta royalties and higher EPKINLY net product sales.
-
Net Profit Falls on Costs and Debt
Net profit was $698 million versus $932 million, as operating expenses rose 35% to $2,018 million and financial items swung to a $263 million net expense, including $256 million of interest and $68 million of fee amortization on the Merus acquisition borrowings.
-
EPKINLY Sales Up 47%
Global EPKINLY/TEPKINLY net sales were $491 million versus $333 million, with U.S. and Japan net product sales recorded by Genmab of $381 million; DARZALEX royalties contributed $2,057 million on J&J net sales of $12,410 million.
-
2026 Guidance Maintained
Genmab reiterated guidance first published August 6, 2026: revenue of $4.325-4.525 billion and adjusted operating profit of $1.065-1.385 billion, with adjusted operating expenses of $2.81-2.95 billion.
Analysis · GMAB · Life Sciences
Revenue growth is real and broad-based, with DARZALEX royalties of $2,057 million and EPKINLY net sales up 47%. The bottom line went the other way: net profit dropped to $698 million from $932 million as operating expenses rose 35% to $2,018 million and $324 million of interest and fee amortization on the Merus acquisition debt hit financial items. Guidance was held, so the quarter is a cost-and-leverage story rather than a demand story. The bigger swing factor sits outside this report: October's positive Phase 3 readouts for epcoritamab, Rina-S and petosemtamab set up regulatory submissions and potential 2027 launches, and the spend ramp here is the price of that launch build-out.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GMAB was trading at $54.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32B. The 52-week trading range was $23.62 to $59.97. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.